English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

N1-(1-Aryl-2-(1H-imidazol-1-yl and 1H-1,2,4-triazol-1-yl)-ethylidene)-pyridine-2-carbo xamidrazone derivatives were synthesized and tested for their in vitro antifungal and antimycobacterial activity. Some compounds showed a very good activity against the tested clinical isolates of Candida albicans 685 and Candida glabrata 523. The same compounds exhibited an interesting, even if moderate, activity against the tested strain of Mycobacterium tuberculosis H 37Rv. Preliminary molecular modeling investigations yielded free energy of binding values in harmony with the corresponding experimental findings. They further revealed that an optimized balance of opposing electrostatic contributions must be realized to gain tight enzyme-inhibitor binding.

arkivoc

Antifungal and antimycobacterial activity of new N1-[1-aryl-2-(1H-Imidazol-1-yl and 1H-1,2,4-triazol-1-yl)-ethylidene]-pyridine-2-carboxamidrazone derivatives: A combined experimental and computational approach.